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Increased plasminogen binding is associated with
metastatic breast cancer cells: differential expression
of plasminogen binding proteins
M Ranson, NM Andronicos, MJ O'Mullane and MS Baker
Department of Biological Sciences, University of Wollongong, Wollongong, NSW Australia 2522
Summary Overexpression of urokinase-type plasminogen activator and its receptor correlates with metastatic capacity in breast cancer. In
this study we show that the urokinase/urokinase receptor-overexpressing, metastatic human breast cancer cell line MDA-MB-231 (1) bound
significantly more cell-surface plasminogen in a lysine-dependent manner and (2) was capable of generating large amounts of plasmin
compared with the non-metastatic cell lines MCF-7 and T-47D. In addition, distinct plasminogen binding proteins were detected in the plasma
membranes of the cell lines, suggesting heterogeneity of binding proteins. Plasminogen binding was analysed using a combination of dual-
colour fluorescence flow cytometry and ligand histochemistry (for comparative and cellular localization of ligand binding), and fluorimetry (for
Scatchard analysis). Apart from revealing the greater plasminogen binding capacity of MDA-MB-231 cells, flow cytometry and histochemistry
also revealed that, in all three cell lines, non-viable or permeabilized cells bound significantly more plasminogen in a lysine-dependent
manner than viable or non-permeabilized cells. Viable MDA-MB-231 cells bound plasminogen with moderate affinity and high capacity
(Kd = 1.8 gm, receptor sites per cell 5.0 x 107. Our results indicate that differences in cell surface-specific plasminogen binding capacity
between cell lines may not be detectable with binding techniques that cannot distinguish between viable and non-viable cells.
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The acquisition ofthe malignantphenotype requires a multitude of
complex processes, including a loss ofcontrol ofcell proliferation
(e.g. via oncogene activation), higher metabolic requirements and
the ability of cells to invade and metastasize throughout the body
(reviewed in Evans, 1991). The processes of tumour cell invasion
and metastasis are likely to involve the inappropriate expression of
proteinases (reviewed in Mignatti and Rifkin, 1993). The serine
proteinases of the plasminogen activation proteolytic cascade
appear to play an important role in this process (reviewed in Duffy,
1993; Mignatti and Rifkin, 1993). Plasminogen, a broad-spectrum
serine endopeptidase zymogen, is secreted in its mature form as a
single-chain glycoprotein containing a N-terminal glutamic acid, a
binding domain [consisting offive kringle structures on which the
lysine binding sites (kringles 1, 4 and 5) are located] and a
protease domain (reviewed in Castellino, 1995). When activated
by urokinase plasminogen activator (uPA) or tissue plasminogen
activator, plasminogen is converted into the active twin-chain
proteinase, i.e. plasmin (Castellino, 1995). It is clear that tissue
plasminogen activator and plasminogen bind to and mediate fibrin
clot dissolution, whereas uPA is primarily involved in pericellular
proteolysis as it binds to specific cell-surface glycosyl phospha-
tidylinositol-anchored receptors (uPAR) (Moller, 1993).
The uPA-uPAR interaction on cancer cell surfaces is a key
event that results in increased in vitro matrix degradation and
migration (Duffy, 1993; Mignatti and Rifkin, 1993). In the absence
of extracellular proteolysis, inactive uPA binding has been shown
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to induce cell migration by signal transduction events via uPAR
(Busso et al, 1994). Nevertheless, dissolution of matrix via plas-
minogen activation at the cell surface is importantformetastasis to
occur. Indeed, the inhibition of uPA and plasmin by specific
inhibitors or antibodies, or antisense inhibition ofuPARresulted in
decreased plasminogen activation and hence decreased extracel-
lular matrix degradation in vitro or decreased metastasis in nude
mouse models with various cancer cell lines (Baker et al, 1990;
Kook et al, 1994), including human breast cancer cell lines (Holst-
Hansen et al, 1996; Stonelake et al, 1997). In vitro invasiveness
has been correlated with uPA and plasmin activity as well as high
uPAR and plasminogen activator inhibitor type 1 (PAI-1) protein
levels in human breast cancercell lines (Holst-Hansen et al, 1996).
Long-term studies have shown that increased primary breast
cancer biopsy levels of the uPA antigen are related to shorter
disease-free period and reduced survival in women with breast
cancer (Duffy, 1993). It is now apparent that the combined overex-
pression ofuPA, uPAR and plasminogen activator inhibitor type 1
(PAl-1) in human breast carcinoma tissue is associated with breast
cancer progression and can also be related to shorter disease-free
period and reduced survival (Janicke et al, 1991; Christensen et al,
1996; Costantini et al, 1996; Nielsen et al, 1996), while elevated
PAI-2 levels are related to afavourable prognosis in primary breast
cancer (Foekens et al, 1995).
Plasminogen has been immunologically localized to cell
surfaces in sections of human mammary carcinoma tissue (Burtin
et al, 1993) and to the invasive front of cutaneous melanoma
lesions (De Vries et al, 1996). Cell-surface localization of plas-
minogen would be advantageous for cell migration, as the activa-
tion ofreceptor-bound plasminogen to plasmin is enhanced while
cell-bound plasmin is protected from circulating inhibitors (e.g.
a2-antiplasmin) (Plow and Miles, 1990). Plasminogen binds to a
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number of different cell types via its kringle domains within a
range of affinities (dissociation constants (Kd) = 0.1-5 gM) and
receptor sites per cell (104-108), and various candidate receptors
have been identified from endothelial cells (Cesarman et al, 1994),
neurons (Parkkinen and Rauvala, 1991), monocytoid cells (Miles
et al, 1991) and breast cancer cells (Hembrough et al, 1995).
Plasminogen also interacts with several extracellar matrix compo-
nents, such as type IV collagen (Stack et al, 1992), and with
non-proteinaceous cellular moieties, such as gangliosides (Miles
et al, 1989).
Approximately 20-30% of all human breast cancers over-
express two closely related receptor tyrosine kinases, epidermal
growth factor receptor (EGFR) and/or p185HER2/neu (c-erbB-2), and
this phenotype is associated with more aggressive tumour growth
and reduced patient survival (Singleton and Strickler, 1992). In
contrast, breast cancer cell lines that are oestrogen receptor (ER)
positive and have little or no EGFR have a fundamentally non-
metastatic phenotype (Lee et al, 1990). The presence ofER is also
inversely related to uPA and uPAR levels in breast carcinomas and
cell lines (Mignatti and Rifkin, 1993; Long and Rose, 1996). In
addition, it is apparent that breast cancer cell lines that readily
form tumours and metastasize in nude mouse models and/or are
invasive in in vitro models of metastases (e.g. MDA-MB-231
cells) (Thompson et al, 1992) tend to be EGFR(+)/erbB-2
protein(+) and ER(-) (Lee et al, 1990), as well as uPA/uPAR(+)
(Holst-Hansen et al, 1996). Interestingly, EGFR stimulation or c-
erbB-2 overexpression in human breast cancer cells enhances the
expression and secretion of uPA and expression of uPAR (Long
and Rose, 1996; Connolly and Rose, 1997).
The purpose of this study was to characterize the cell-surface
plasminogen binding events in three human breast cancer cell
lines. We report that in these cell lines, elevated cell-surface
lysine-dependent plasminogen binding and plasmin formation is
associated with metastatic capacity and other parameters
(EGFR/erbB-2 status, ER status, uPA/uPAR status) commonly
associated with human breast cancer malignancy. We also found
that non-viable cells bound 100-fold more plasminogen than
viable cells and that the presence of non-viable cells must be
considered when determining cell-surface binding parameters. In
addition, a distinct plasminogen receptor profile was evident in the
plasma membranes of the breast cancer cell lines, suggesting
heterogeneity ofplasminogen binding proteins in these cell lines.
MATERIALS AND METHODS
Materials
RPMI 1640, L-glutamine and Hank's buffered salt solution were
purchased from Trace Biosciences (Castle Hill, NSW, Australia).
Fetal calf serum was obtained from CSL (Parkville, Victoria,
Australia). Tranexamic acid, E-amino-n-caproic acid (EACA),
aprotinin, polyvinyl pyrrolidine (PVP-40), bovine serum albumin
(fraction V) (BSA) and fluorescein isothiocyanate (isomer 1)
(FITC) were purchased from Sigma Chemical (St Louis, MO,
USA). Biotin-X-NHS was from Calbiochem (San Diego, CA,
USA). Z-lysine thiobenzylester was from Peninsula Laboratories
(CA, USA). Enhanced chemiluminescence (ECL) detection kit
was purchased from Amersham International (Buckinghamshire,
UK). Molecular weight protein standards were obtained from
Novex (San Diego, CA, USA). The Dako LSAB+ kit was from
Dako (CA, USA).
Specific proteins and antibodies
Human recombinant ax-enolase was prepared as previously
described (Andronicos et al, 1997). Active human uPA was from
Serono (Sydney, NSW, Australia). Plasminogen, plasmin, the
plasmin-specific substrate Spectrozyme-PL, mouse anti-human
uPAR monoclonal antibody (no. 3696) and rabbit anti-human
uPAR polyclonal antibody (no. 399R) were purchased from
American Diagnostica (Greenwich, CT, USA). Rabbit anti-human
plasminogen polyclonal antibody and horseradish peroxidase-
conjugated goat anti-rabbit polyclonal antibody were purchased
from Calbiochem (San Diego, CA, USA). Mouse anti-human
EGFR monoclonal antibody (clone LAI) was obtained from
Upstate Biotechnology (Lake Placid, NY, USA), while mouse
anti-human Neu (9G6) monoclonal antibody was obtained from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). SBU-LCA
IgG2a monoclonal antibody against sheep lymphocyte markers was
from the Centre for Animal Biotechnology (Melbourne, Victoria,
Australia), and FITC-conjugated anti-mouse IgG was from Silenus
(Sydney, NSW, Australia).
Cell culture
The human breast cancer cell lines used in this study (MCF-7,
MDA-MB-231, T-47D) were gifts from Professor R Sutherland
(Garvan Institute of Medical Research, Sydney, NSW, Australia).
The cell lines were all routinely cultured in RPMI-1640 supple-
mented with 10% (v/v) heat-inactivated fetal calf serum. The T-
47D cell line was cultured in the above media containing insulin
(0.2 IU ml-'). The cells were incubated in a humidified incubator
at 37°C with a 5% carbon dioxide-95% air atmosphere.
Whole-cell lysate preparation
Confluent cells were washed with sterile ice-cold phosphate-
buffered saline (PBS) and harvested by scraping with a rubber
policeman. The cells were incubated with cell lysis buffer [50 mm
Tris-HCl (pH 8.0), 150 mm sodium chloride, 4 mM magnesium
chloride, 10% glycerol, 5 mm EDTA, 1 mM phenylmethylsulfonyl
fluoride, 0.1% (v/v) Triton X-100, 0.5% (w/v) sodium deoxy-
cholate] at 40C for 20 min. The resulting lysates were collected
and centrifuged at 14 000g for 15 min at 4°C and the supernatant
stored at-20°C until required.
Membrane preparations
Total cellularmembrane
Confluent cells were washed and harvested by scraping in ice-cold
PBS and subjected to hypotonic shock in a small volume of ice-
cold hypotonic buffer [3 mm sodium phosphate (pH 7.4), 5 mm
EDTA, 1 mm phenylmethylsulfonyl fluoride]. The suspensions
were then sonicated with several 20-s bursts at high power with a
Branson Sonifier 250 (CT, USA), checked under a microscope for
effective disruption of the cells and then centrifuged at 500 g for
5 min. The supernatant was centrifuged at 46 000g for 30 min and
the resultant supernatant was frozen in aliquots at -70°C. The
crude membrane pellet was resuspended in 5 ml of ice-cold 5 mM
EDTA/PBS, briefly resonicated, diluted to 50 ml with EDTA/PBS
and centrifuged at 46 000 g for 30 min. The resulting membrane
pellet was resuspended in 1 ml of EDTA/PBS with brief sonica-
tion, then aliquoted and stored at -70°C.
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Plasma membrane
Confluent cells were washed, harvested, subjected to hypotonic
shock as above and then homogenized in a Dounce homogenizer.
Plasma membranes were then isolated using the aqueous two-
phase PEG polymer/dextran system as described by Rana and
Majumder (1987).
Western blotting and plasminogen ligand blotting
Whole-cell lysates and membrane preparations were boiled in
sample buffer, fractionated on 10% or 12% SDS-PAGE gels, and
parallel gels were either stained with Coomassie blue or trans-
ferred to PVDF membranes at 100 V for 1 h or 30 V overnight at
4°C. For Western blotting, the membranes were washed in TBST
[50 mM Tris-HCl (pH 8.0), 150 mm sodium chloride, 0.05% (v/v)
Tween-20], blocked in 10% milk powder/TBST at room tempera-
ture for 1-2 h, rinsed in TBST, then incubated with the primary
antibody in 2% milk/TBST for 1 h at room temperature. After
extensive washing, the membrane was re-blocked for 20 min with
6% milk/TBST and incubated with the appropriate secondary anti-
body diluted 1:2000 in 2% milk/TBST. After three washes with
TBST and one wash with TBS, the immune complexes were
detected by ECL.
For ligand blotting, membranes were washed once with TNCM
[50 mM Tris-HCl (pH 7.5), 150 mm sodium chloride, 2 mM
calcium chloride, 3 mM magnesium chloride] and blocked with
TNCM/2% PVP-40 overnight at room temperature. The
membranes were then probed with 5 nM glu-plasminogen in the
absence or presence of 100 mM EACA in TNCM/PVP-40
containing 0.05% (v/v) Tween 20 (TNCMT) for 45 min and
washed for 1 h with three changes of TNCMT. After re-blocking
for 30 min, a 1:2000 dilution ofrabbit antiplasminogen polyclonal
antibody in TNCMT/PVP-40 was added and incubated with the
membrane for 1 h. This was followed by three 5-min washes,
re-blocking for Omin and probing with a 1:1000 dilution of
horseradish peroxidase-conjugated goat anti-rabbit polyclonal
antibody in TNCMT/PVP-40 for 1 h. This was followed by three
washes with TNCMT and one wash with TNCM. The blots were
then developed by ECL.
Urokinase plasminogen activator activity and plasmin
activity assays
The activity of uPA in the membrane preparations was measured
as described by Coleman and Green (1981). Briefly, membrane
preparations (10 ,ug of protein per well) were preincubated with
glu-plasminogen (1 ,UM) for 45 min at 37°C, followed by a further
45-min incubation with the chromogenic plasmin substrate, Z-
lysine thiobenzylester (170,M). Colour development was read at
414 nm. Standard curves were constructed using uPA. Plasmin
activity was measured using the Spectrozyme-PL assay (American
Diagnostica; conditions are described in the figure legend).
Standard curves for the uPA and plasmin assays were constructed
using uPA and plasmin respectively.
Flow cytometry and fluorimetry
Human glu-plasminogen, aprotinin or BSA in PBS were conju-
gated with FITC as described by Goding (1976). Unconjugated
FITC was separated by a PD-10 gel filtration column equilibrated
with PBS/0.1% azide. FITC-glu-plasminogen was able to bind
lysine-Sepharose 4B, while FITC-aprotinin was able to inhibit
plasmin activity, indicating that FITC conjugation did not inhibit
the function ofthese proteins.
Subconfluent, adherent cells that had been in culture for 48 h
without a change of media were harvested by rinsing flasks twice
with cold PBS (pH 7.2) and then detaching with 5 mM EDTA/PBS
at 37°C for 5 min. For FITC-glu-plasminogen binding assays, cells
were washed twice and resuspended in freshly made and chilled
binding buffer (Hanks buffered salt solution containing 1 mM
Table 1 Metastatic phenotype of three human breast cancer cell lines
Cell linesa
Cell characteristic Method of analysesb MDA-MB-231 MCF-7 T-47D
Morphology Refer to Figure 3 Spindle-shaped Epithelial Epithelial
Invasion and metastases in nude mice Local invasion and lymph node Yesc No Noc,d
involvement and/or presence of (3/5 mice) (0/8 mice)
distant metastases (0/20)c,d
EGFR Western blotef .... +
neu/c-erbB-2 Western bloteg ++ +
Oestrogen receptor Immunohisto chemistryh ++
uPAR Western bloteJ ++++ ++ +
Flow cytometryi 63 + 7 MFI 10 + 3 MFI 4 ± 0.3 MFI
uPA activity (mlU mg-') Coleman and Green assayk 273 + 14 59 + 8 14 ± 0.4
aAll values shown are taken from representative experiments. bRefer to Materials and methods for detail. cTumours were often vascularized and lymph
nodes enlarged. dInformation obtained from Thompson et al (1992). eBand intensity was scanned and quantified by densitometry (Molecular Analyst
Software, Bio-Rad) with blanks subtracted from all values. The intensities were rated as: -, negative; +, weakly positive; ++, moderately positive;
+++, strongly positive; ++++, very strongly positive. 'A major band of approximately 170 kDa detected. Performed with total and/or plasma membrane
preparations. gA single major band of approximately 185 kDa detected. Performed with total and/or plasma membrane preparations. hIntensity of brown
staining rated as: -, negative; +, weakly positive; ++, moderately positive; +++, strongly positive; ++++, very strongly positive. iA major band of
approximately 55 kDa detected. Performed with total and/or plasma membrane preparations. iMFI, mean fluorescence intensity. Values shown are means
± s.d. (n> 3). kPerformed with total membrane preparations. Values shown are means + s.d. (n> 3).
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Figure 1 Cell-surface lysine-dependent plasminogen binding capacity of
breast cancer cell lines. Cells were incubated with FITC-glu-plasminogen
(0.5 lM) in the absence (total binding) or presence (lysine-independent binding)
of 1 mM tranexamic acid, washed, resuspended in buffer containing propidium
iodide and analysed by dual-colour flow cytometry. (A) The bar graph shows
lysine-dependent binding (obtained by subtracting lysine-independent binding
from the total binding) calculated from individual histogram plots in which the
fluorescence intensity values were gated to include viable cells only. Values
shown are means ± s.d. (n = 4). (B) A representative density plot of
fluorescence intensities due to FITC-glu-plasminogen binding (FL1-FITC) vs
propidium iodide uptake (FL2-PI) in MDA-MB-231 cells. Viable and non-viable
cell gates were set around cells that excluded and included PI respectively. (C)
Representative histogram plots of FITC-glu-plasminogen binding to viable
MDA-MB-231 cells. Plg, FITC-glu plasminogen; Plg + TA, Plg and tranexamic
acid. No shift in fluorescence intensities relative to autofluorescence was seen
when cells were incubated with 0.5gM FITC-BSA
calcium chloride, 1 mm magnesium chloride, 20 mM HEPES
(pH 7.4) and 0.1% BSA) at a concentration of 1 x 106 cells ml-'. A
200-,ul aliquot ofthe cell suspension was pelleted andresuspended
in 200gl of binding buffer containing FITC-glu-plasminogen in
the presence or absence of the lysine analogue tranexamic acid.
After incubation for 1 h on ice in the dark, the cells were washed
and resuspended in 250gl of binding buffer containing the non-
vital dye propidium iodide (5 gg ml-'). Cell-associated fluores-
cence was then measured by dual-colour flow cytometry
(FACSort, Becton-Dickinson). By using dual-colour flow cytom-
etry it was possible to distinguish between two parameters based
on the different fluorochromes, i.e. ligand binding (FITC produces
a strong green fluorescence) and cell viability (propidium iodide
binds to DNA and dsRNA and produces a strong red colour)
(Darzynkiewicz et al, 1994). This technique was used to establish
'gates' - the exclusion ofpropidium iodide for a viable 'gate', the
inclusion ofpropidium iodide for a non-viable 'gate'.
Flow cytometry is a semi-quantitative technique and ligand
binding, measured in fluorescence units, cannot be related toinput
protein concentration. Therefore, in order to analyse specific
binding isotherms by Scatchard transformation, thebinding exper-
iments described above were analysed by fluorimetry. Briefly,
after the final wash step, the cells were resuspended in 2 ml of
binding buffer without propidium iodide, and the extrinsic fluores-
cence ofFITC-glu-plasminogen was measuredusing a fluorimeter
(F-4500, Hitachi) with a slit width of 0.5 mm. Excitation and
emission wavelengths were set at 488 nm and 521 nm respec-
tively. A FITC-glu-plasminogen standard curve was constructed to
relate fluorescence units to plasminogen concentration taking into
account the ratio of FITC per molecule ofplasminogen. To deter-
mine the proportion of non-viable cells, parallel dual-colour flow
cytometry experiments were performed andtheyconsistently indi-
cated that 10-15% of the cell samples were non-viable according
to propidium iodide uptake.
Cell-surface plasmin was detected using dual-colour flow
cytometry as described above with the following modifications.
Cells were preincubated in the absence or presence of unlabelled
glu-plasminogen (0.5 gM) for 30 min at room temperature
followed by incubation on ice for 1 h with FITC-aprotinin (1 jM)
in the absence or presence of a 50-fold excess of unlabelled
aprotinin. The cells were then washed, resuspended in buffer
containing propidium iodide and measured as described above.
For the detection ofcell-surface uPAR, indirect immunofluores-
cence staining was performed. Cells were incubated with either an
irrelevant isotype control (SBU-LCA IgG2a) or anti-human uPAR
monoclonal antibody for 30 min on ice (10 jig ml-' in cold
RPMI/0.1% BSA), washed with 1 ml of cold RPMI/O.1% BSA
and incubated with FITC-conjugated anti-mouse IgG (1:50 dilu-
tion of stock in cold RPMI/O.1% BSA) for 30 min on ice in the
dark. The cells were washed again, resuspended in 0.5 ml of
PBS/0.1% sodium azide containing 5 jg ml-' propidium iodide,
and the cells were immediately analysed by dual-colour flow
cytometry as described above.
In all the fluorescence-based experiments, autofluorescence was
subtracted. All data was analysed using CELLQuest software
(Becton-Dickinson).
Plasminogen ligand histochemistry
Cells were passaged onto sterile glass coverslips in their appro-
priate media and allowed to adhere and spread for at least 48 h.
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The cells were then washed three times with PBS and fixed with
glutaraldehyde (1% (v/v) in PBS) for 1 h at room temperature.
Fixation was necessary as unfixed cells consistently rounded up
and floated off the coverslips. After washing twice with PBS, the
cells were either permeabilized by incubation with 0.2% (v/v)
Triton X-100 for 2 min at room temperature (to allow ligand to
reach intracellular binding moieties in the glutaraldehyde-fixed
cells; Harlow and Lane, 1988) or left in PBS. After two washes
with PBS, the permeabilized and non-permeabilized cells were
incubated with 3% hydrogen peroxide for 5 min, rinsed with PBS
and incubated in PBS/0.1% BSA containing either 0.2 ,UM
biotinylated BSA or plasminogen (prepared as previously
described by Andronicos et al, 1997) in the absence or presence of
5 mM tranexamic acid for 30 min at room temperature. The cells
were washed three times with PBS, incubated with streptavidin
peroxidase and finally with the diaminobenzidine chromogen
substrate solution provided with the Dako LSAB+ kit. After
rinsing with PBS, the cells were viewed using a video camera
(National Panasonic) attached to an inverted compound micro-
scope (Leica, Germany). Colour images of the cells (original
magnification x400) were captured by a Power PC (Macintosh
8500/20) using Apple Video Player software (Macintosh).
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Invasive and metastatic characteristics of human
breast cancer cell lines
Local tissue invasion and metastatic ability of the MDA-MB-231,
MCF-7 and T-47D cell lines in nude mice has been characterized
in detail by Thompson et al (1992). Only the MDA-MB-231 cell
line was found to be invasive and metastatic. To confirm the in
vivo characteristics ofthese cell lines 1-2 x 106 cells per site were
injected into the neck region (s.c.) of male 4- to 6-week-old Swiss
nu/nu nude mice. Animals were sacrificed when tumours became
2.5 cm in diameter or after 60 days, whichever arose first. Primary
tumours and adjacent lymph nodes were excised and examined
histologically.
RESULTS
Metastatic phenotypes of human breast cancer cell
lines
In order to confirm that the metastatic phenotypes of the human
breast cancer cell lines MDA-MB-231, MCF-7 and T-47D
concurred with published data, the invasive and metastatic ability
of these cell lines in a nude mouse model were compared with
morphology, EGFR, c-erbB-21neu, ER and uPAR expression, and
uPA activity (Table 1). These particular characteristics ofthe three
breast cancer cell lines have not been compiled previously in one
study but each characteristic was highly comparable to published
data from several sources (Lee et al, 1990; Thompson et al, 1992;
Hoist-Hansen et al, 1996). The MDA-MB-231 cells had a spindle-
shape morphology, were EGFRIneu(+) and ER(-), were invasive
and metastatic in vivo and were highly positive for uPAR protein
and uPA activity (Table 1). In contrast, the MCF-7 and T-47D cell
lines had a more epithelial morphology, contained little or no
EGFR/neu protein, were ER(+) and were neither invasive nor
metastatic in vivo (although MCF-7 cells are known to form
tumours in the presence of oestrogen; Thompson et al, 1992).
Interestingly, the levels of plasma membrane and cell-surface
uPAR protein were markedly reduced in the MCF-7 (four- to
a) a)
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Figure 2 Plasminogen binding to MDA-MB-231 cells. (A) MDA-MB-231
cells were incubated with increasing concentrations of FITC-glu-plasminogen
in the absence (X) or presence of 1 mm tranexamic acid (+) and analysed by
dual-colour flow cytometry. The lysine-dependent plasminogen binding of
viable cells (A) was calculated as described in the legend to Figure 1. The
values shown are means ± s.d. (n = 3) from a representative experiment.
(B) Representative Scatchard plot of lysine-dependent FITC-glu-plasminogen
binding. This plot was derived from binding data generated by fluorimetry
measurements and includes binding due to both viable and non-viable cells
six- fold respectively) and even more so in T-47D (10- to 15-fold
respectively) compared with levels in MDA-MB-231 cells. In
agreement, a similar pattern was found for plasma membrane uPA
activity (at least threefold for MCF-7 and 18-fold for T-47D)
compared with plasma membrane levels in MDA-MB-231 cells.
The results in Table 1 confirm that cells with a malignant pheno-
type are less differentiated and overexpress uPAR than the more
differentiated and non-invasive cell lines.
Cell-surface plasminogen binding on metastatic vs
non-metastatic breast cancer cells
Fluorescence studies
The ability of plasminogen to interact with the cell surface was
assessed by dual-colour flow cytometry. This technique was able
to distinguish plasminogen binding to viable cells (cell-surface
specific binding) from non-viable cells (binding to cell surfaces
British Journal ofCancer (1998) 77(10), 1586-1597 0 CancerResearch Campaign 1998Plasminogen binding to breast cancercells 1591
D
F
Figure 3 Plasminogen ligand histochemistry of non-permeabilized breast cancer cells. Fixed and non-permeabilized MDA-MB-231 (A-C), MCF-7 (D-F) and
T-47D (G-1) cells were incubated with biotinylated glu-plasminogen (0.2 gM) in the absence (A, D, G) or presence (B, E, H) of 5 mM tranexamic acid, followed by
incubation with streptavidin-HRP. Lower panels (C ,F, I) show a lack of streptavidin-HRP interaction and subsequent colour reaction with cells that had been
incubated with biotinylated BSA (0.2 pM). The arrow in panel (D) points to cellular debris
and intracellular moieties). Density plots of fluorescence intensity
due to FITC-glu-plasminogen binding vs propidium iodide uptake
were used to establish 'gates' based on viability (Figure iB;
described in detail in Materials and methods). Cells that excluded
the propidium iodide were gated as viable, whereas cells staining
with propidium iodide were gated as non-viable (Figure 1B).
Based on these parameters, fluorescence intensity due to cell-
surface specific plasminogen binding only can be presented as
histogram plots, as shown in Figure IC. The histogram plots were
used to calculate cell-surface lysine-dependent plasminogen
binding (Figure 1A) and indicated that, while the MCF-7 and T-
47D cell lines bound similarly low but detectable amounts ofplas-
minogen (8.0 ± 0.8 and 9.5 ± 2.3 fluorescence units respectively),
the MDA-MB-23 1 cell line bound significantly more plasminogen
(21.2 ± 3.6 fluorescence units) than either the MCF-7 or the T-47D
cell line.
Interestingly, the amount of FITC-glu-plasminogen binding to
non-viable cells was consistently two orders of magnitude higher
than to viable cells (refer to Figure 1B) and this was lysine depen-
dent (data not shown). This phenomenon was also found in the
MCF-7 and T-47D cell lines (data not shown).
Cell-surface plasminogen binding to MDA-MB-231 cells was
lysine- and concentration-dependent, indicating a specific inter-
action (Figure 2A). At all plasminogen concentrations tested,
binding to MCF-7 and T-47D cells was minimal compared with
MDA-MB-231 cells (data not shown). The concentrations ofplas-
minogen required to saturate binding [e.g. to saturate binding to
pure recombinant cx-enolase, at least 10 tM (-I mg ml-') of plas-
minogen was necessary; Andronicos et al, 1997] were found to
render most of the cells non-viable (data not shown). Thus, it was
not possible to measure cell-surface plasminogen binding to viable
cells at high concentrations. The reason for this apparent toxic
effect is unclear, but it is unlikely to be due to a loss of membrane
integrity resulting from enzymatic activity, as the binding experi-
ments were all performed on ice. Despite this, the lysine-
dependent plasminogen binding to MDA-MB-23 1 cells was
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Figure 4 Plasminogen ligand histochemistry of permeabilized breast cancer cells. Same as for legend to Figure 3 except that, afterfixation, cells were
permeabilized with Triton X-100 as described in Materials and methods
further characterized by FITC-glu-plasminogen binding and fluo-
rimeter analysis. This technique is similar in principle to radiola-
belled plasminogen binding analysis techniques that allow
quantitation of binding parameters by Scatchard analysis.
However, these techniques cannot take into account any binding as
a result of even a small percentage of non-viable cells, which are
invariably present in most cell preparations, regardless of the care
taken to prevent cell damage. Nevertheless, when lysine-depen-
dent plasminogen binding curves were transformed into Scatchard
plots, the best fit for the data was curvilinear (Figure 2B), indi-
cating two classes ofbinding sites. The Kd values for plasminogen
binding to MDA-MB-231 cells were 1.8 ± 0.6 x 10-6 M for the
higher affinity site and 2.0 + 0.9 x I04 M for the lower affinity site.
The numbers of binding sites per cell were 5.0 ± 1.6 x 107 and
3.9 ± 1.8 x 109 for the higher and lower affinity sites respectively.
This difference in number of binding sites per cell (two orders of
magnitude) is comparable to the difference in capacity seen on
viable and non-viable cells by flow cytometry (see above and refer
to Figure IB) and suggests that the lower affinity sites are attribut-
able to non-viable cell plasminogen binding.
Ligand histochemistry studies
The plasminogen ligand histochemistry technique allowed plas-
minogen binding capacity to be visualized on viable cells that were
attached and spread onto a substrata. The differences seen by flow
cytometry between the cell lines (Figures 1 and 2) were reproduced
by plasminogen ligand histochemistry with non-permeabilized
cells (Figure 3). The highest amount ofpositive brown staining was
seen in the MDA-MB-231 cell line (Figure 3A) compared with the
MCF-7 (Figure 3D) or T-47D (Figure 3G) cell lines. In the presence
of excess tranexamic acid plasminogen binding was greatly
reduced in all three cell lines (Figure 3B, E and H), confirming that
the cell lines bound plasminogen in a lysine-dependent manner.
The ligand histochemistry technique also showed that, while
staining was diffuse over the cell surfaces, the degree of plas-
minogen binding within each cell line was heterogeneous. This was
especially apparent in the MCF-7 and T-47D cell lines, in which
some cells showed distinctive staining while others appeared to be
completely negative (Figure 3D and G).
Deliberate permeabilization of the cells resulted in an enhance-
ment of the amount of plasminogen binding that could be
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Figure 5 Plasminogen ligand blotting of breast cancer cell whole-cell lysates. Whole-cell lysates (15 gg per lane) and human recombinant a-enolase (r-a-
enolase, 5 ,ug per lane) were separated by 12% SDS-PAGE under reducing conditions and either stained with Coomassie Blue (A) or transferred and subjected
to ligand blotting using 5 nm glu-plasminogen in the absence (B) or presence of 100 mm e-amino-n-caproic acid (C). Blots (B) and (C) were derived from gels
run, transferred and probed in parallel and were exposed onto the same piece of autoradiograph film so that a direct comparison could be made between them.
Glu-plasminogen binding proteins were detected using an anti-plasminogen polyclonal antibody. The arrows point to bands with apparent molecular masses of
50 kDa and 30 kDa
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Figure 6 Plasminogen ligand blotting of breast cancer cell plasma membranes. Same as for legend to Figure 5 except that plasma membrane fractions (15 ,ug
per lane) were used instead of whole-cell lysates
substantially reduced in the presence of tranexamic acid in all
three breast cancer cell lines (Figure 4). The distribution of
staining in these cells appeared to be diffuse in the cytoplasm and
on the cell surface, and was not associated with the nucleus. The
results in Figure 4 suggest that permeabilization allows plas-
minogen to bind to intracellular moieties not otherwise available at
the cell surface and that there are many more plasminogen binding
intracellular moieties than cell surface ones in all the cell lines.
These ligand histochemistry data correlated well with the flow
cytometry data, which demonstrated that plasminogen binding
was substantially greater in non-viable cells than in viable cells
(refer to Figure 1B). Interestingly, while the permeabilized MDA-
MB-23 1 cells (Figure 4A) still appeared to bind more plasminogen
than the permeabilized MCF-7 (Figure 4D) and T-47D (Figure 4F)
cell lines, this difference between the three cell lines was not as
apparent as in the non-permeabilized cells (Figure 3). This may be
as a result of the sheer magnitude of plasminogen binding in
permeabilized cells, which has the effect ofdiminishing the differ-
ences in plasminogen binding capacity between the cell lines.
Total cellular and membrane-associated plasminogen
binding proteins in the three breast cancer cell lines
Several bands were detected in ligand blots of whole-cell lysates
from the breast cancer cell lines (Figure 5). Ofthese, two were major
plasminogen binding bands (apparent molecular masses 50 kDa and
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Figure 7 Plasmin formation by breast cancer cells. Breast cancer cell
plasma membrane preparations (2 .tg) were preincubated with 0.5 tM
plasminogen for 30 min at room temperature, followed by a 5-min incubation
in the absence (U) or presence (9) of 1 mm aprotinin. Plasmin activity was
then measured at 370C over 20 min using the Spectrozyme PL substrate
(0.25 mm final concentration). Plasmin activity in the absence of plasminogen
and aprotinin was also measured (3). The inset shows specific FITC-
aprotinin binding to viable MDA-MB-231 cells as assessed by dual-colour
flow cytometry (refer to Figure 1 B). The specific binding was calculated by
subtracting binding in the presence of a 50-fold excess of unlabelled aprotinin
from the total binding. The values shown are means + s.d. (n = 3) from
representative experiments
30 kDa) and were present at similar levels in all three cell lines
(Figure 5B). These bands corresponded to plasminogen binding
proteins because the lysine analogue EACA completely abolished
the binding ofplasminogen to these proteins (Figure SC).
Ligand blots of plasma membrane proteins indicated a distinct
plasminogen binding protein profile on each of the three cell lines
(Figure 6). The MCF-7 plasma membranes contained three major
bands with apparent molecular masses of 57 kDa, 47 kDa and
33 kDa, as well as two minor bands of40 kDa and 36 kDa (Figure
6B). The 47-kDa and the 33-kDa bands in the MCF-7 plasma
membranes (Figure 6B) corresponded to the 50-kDa and 30-kDa
bands, respectively, in the MCF-7 whole-cell lysate (Figure 5).
While the MDA-MB-231 and T-47D plasma membranes did not
contain detectable amounts of the 57-kDa or 47- to 50-kDa bands
seen in the MCF-7 plasma membranes, the 30- to 33-kDa band
was present in all plasma membranes as a major band (Figure 6B).
The MDA-MB-231 plasma membranes contained two other major
bands with apparent molecular masses of 36 kDa and 26 kDa
(Figure 6B). The T-47D plasma membranes also contained the 36-
kDa band but in lower concentration than in the MDA-MB-231
plasma membranes (Figure 6B). In all ligand blots the plas-
minogen binding protein r-ox-enolase (Andronicos et al, 1997) was
used as a positive control. In each case the presence of EACA
inhibited plasminogen binding to the protein (Figures SC and 6C).
Plasmin generation is associated with high
plasminogen binding capacity and uPA activity
The ability to generate plasma membrane-associated plasmin
activity was compared between the three breast cancer cell lines
(Figure 7). Not surprisingly, the MDA-MB-231 cells, which have
the highest plasminogen binding capacity and highest endogenous
uPA activity, were highly efficient at generating plasmin. This
activity was dependent on the presence of plasminogen and was
completely inhibited by preincubation with the high-affinity
plasmin inhibitor aprotinin. At a plasminogen concentration of
0.5 jtM, there was no detectable plasmin specific activity in either
the MCF-7 or the T-47D plasma membranes compared with
110 pmol min-' mg-' in the MDA-MB-231 plasma membranes. At
higher concentrations of plasminogen and membrane protein, a
small amount of plasmin specific activity could be detected in the
MCF-7 and T-47D plasma membranes, however this was minimal
compared with that detected for MDA-MB-231 plasma
membranes (data not shown).
In order to show that plasmin was generated on the surfaces of
viable MDA-MB-231 cells, dual-colour flow cytometry was used
to establish 'gates' based on viability (refer to Figure lB and
Materials and methods) using FITC-aprotinin as the ligand. The
use ofFITC-aprotinin as a specific detector ofplasmin activity had
been previously described (Ellis et al, 1987). The inset to Figure 7
show that FITC-aprotinin bound to viable cells but only when
preincubated with plasminogen, suggesting that MDA-MB-231
cells were capable of activating receptor-bound plasminogen on
the cell surface.
DISCUSSION
This study demonstrates that the spindle-shaped, EGFR (+)Ieu(+),
ER(-) and metastatic MDA-MB-231 cells were not only associ-
ated with high uPA activity and uPAR overexpression but that they
also had an increased capacity to bind and activate cell-surface
plasminogen compared with the more differentiated, non-
metastatic cell lines MCF-7 and T-47D. Our results suggest that
expression of cell-surface plasminogen receptors plays a part in
regulating the plasminogen activation cascade and may contribute
to the metastatic phenotype ofthe MDA-MB-231 cell line.
Dual-colour flow cytometry was used initially as a means to
identify cell surface-specific plasminogen binding. However, this
technique also revealed that both viable and non-viable cells could
bind FITC-glu-plasminogen in a lysine-dependent manner.
Moreover, non-viable cells bound two orders of magnitude more
plasminogen than viable cells. This was confirmed by ligand histo-
chemistry, which showed that biotinylated plasminogen binding
capacity was substantially increased in all cell lines after perme-
abilization. This is an important finding as it is very difficult to
harvest adherent cells and maintain them throughout experimental
procedures at 100% viability (we consistently found that 10%,
sometimes up to 20%, of the cells were non-viable as assessed by
propidium iodide uptake by the time cells were analysed by flow
cytometry) and suggests that even a small proportion ofnon-viable
cells could affect evaluation ofauthentic cell-surface plasminogen
binding capacity if viability status is not considered.
Scatchard plots of plasminogen binding data to MDA-MB-231
cells using a single-colour fluorescence technique resulted in
curvilinear plots that are suggestive oftwo classes ofbinding sites.
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Curvilinear Scatchard plots of plasminogen binding have been
reported previously for endothelial cells using aradiolabelled plas-
minogen binding technique (Ganz et al, 1991). The higher-affinity
binding site in the MDA-MB-231 cells had an average Kd of
1.8 gM and 5.0 x 107 binding sites per cell, while the lower affinity
one had an average Kd of 200 gM and 3.9 x 109 binding sites per
cell. The affinity and capacity ofthe higher-affinity site are similar
to that reported for many cell types determined by radiolabelled
glu-plasminogen techniques (Plow and Miles, 1990; Hembrough
et al, 1995) and are within physiological limits as plasminogen is
found in the circulation at 2 gM. The capacity ofthe higher-affinity
site is two orders ofmagnitude higher than the lower-affinity site -
exactly the difference seen in capacity between viable and non-
viable cells by dual-colour flow cytometry. As non-viable cells
were present in all fluorimetry experiments (up to 15% oftotal cell
sample), it is likely that the lower-affinity, very-high-capacity
binding sites are due to non-viable cells. The affinity and capacity
of these non-viable cells implies that it would be hard to saturate
binding. Indeed the non-viable cell binding curves (generated by
dual-colour flow cytometry; data not shown) were linear at the
concentrations of plasminogen used for assessing cell-surface
binding (refer to Figure 2A). Nevertheless, while binding to non-
viable cells may not be physiologically relevant, taken together,
our results suggest that plasminogen binding to non-viable cells is
so large that subtle or even significant differences in cell surface-
specific plasminogen binding capacity between cells can be
missed when measured and analysed with techniques that cannot
distinguish between viable and non-viable cells.
Our results also suggest that there are many more intracellular
plasminogen binding moieties than cell surface ones, regardless of
the cell-surface binding capacity. The 50-kDa plasminogen
binding protein present in the whole-cell lysates of MDA-MB-
231, MCF-7 and T-47D cells may account for at least some of the
increase in plasminogen binding capacity of both the MDA-MB-
231 and the T-47D cell line upon permeabilization. While all ofthe
cell lines expressed plasma membrane-associated plasminogen
binding proteins, the plasminogen ligand blots gave no informa-
tion about the orientation of plasminogen binding proteins within
the plasma membranes of intact cells. Therefore, the presence of
these proteins in the plasma membrane does not necessarily mean
that they would be oriented on the cell surface in such a way that
they could bind pericellular plasminogen. As viable or non-
permeabilized MCF-7 and T-47D cells had minimal cell-surface
plasminogen binding capacity compared with viable or non-
permeabilized MDA-MB-23 1 cells, perhaps only a small propor-
tion of the MCF-7 and T-47D plasma membrane-associated
proteins are physiologically available to bind extracellular plas-
minogen. Upon permeabilization a greater proportion of these
proteins may also become available for plasminogen binding in
the MCF-7 and T-47D cells. It is also possible that non-proteina-
ceous binding moieties, such as gangliosides (Miles et al, 1989),
may account for a significant proportion of the differences in cell-
surface plasminogen binding between the cell lines.
Nevertheless, the ligand blot data indicate that more than one
protein moiety contributes to total cellular plasminogen binding
capacity in these cell lines. The intermediate filament protein
cytokeratin 8 and the glycolytic enzyme ox-enolase are two poten-
tially important receptors that have been isolated from the plasma
membranes of rat hepatocytes (Hembrough et al, 1995), the
lymphoid monocytic cell line U-937 (Miles et al, 1991) and
embryonic rat neurons (Nakajima et al, 1994). Cytokeratin 8 has
been localized to the cell surface of human breast cancer cells
(Hembrough et al, 1995, 1996), and an ct-enolase-like protein with
plasminogen binding ability was isolated from total cell lysates of
two human breast cancer cell lines (Lopez-Alemany et al, 1994).
We have previously demonstrated that the glycolytic enzyme X-
enolase is an authentic plasminogen binding protein and that it is
present as a47-kDa protein in whole-cell lysates ofvarious human
cancer cell lines, including the breast cancer cell lines used in this
study (Andronicos et al, 1997). Using a ['251]plasminogen overlay
assay, Hembrough et al (1996) showed the presence of several
plasminogen binding proteins in the cytoplasm and plasma
membrane fractions ofvarious breast cancer cells. Moreover, they
showed the presence ofa major 55-kDa plasma membrane-associ-
ated plasminogen binding protein in MCF-7 cells, which they
identified as cytokeratin 8. Thus, it is possible that the 47- to 50-
kDa and the 57-kDa plasminogen binding proteins detected in the
current study may be x-enolase and cytokeratin 8 respectively.
The possible identity of the other plasminogen binding proteins
remain unclear. However, the molecular mass ofthe 30- to 33-kDa
protein is similar to that of another plasminogen binding protein,
amphoterin (Parkkinen and Rauvala, 1991).
Thus it is clear that a number of proteinaceous and possibly
non-proteinaceous moieties are likely to contribute to cell-surface
plasminogen binding. It is therefore difficult to design specific
experiments aimed at establishing a direct relationship between
plasminogen binding capacity and metastatic potential without
identifying all of the plasminogen binding moieties on the breast
cancer cell lines. However, Stonelake et al (1997) recently demon-
strated that, in the presence of plasminogen, MDA-MB-231 and
other metastatic breast cancer cell lines, unlike non-metastatic cell
lines, such as MCF-7 and T-47D, had the ability to degrade human
endothelial basement membrane and that this activity was signifi-
cantly inhibited by specific uPA or plasmin inhibitors. These
authors also demonstrated a similar inhibitory effect by lysine
analogues and attributed this result to an inhibition ofplasminogen
binding. These results strongly corroborate our data, which indi-
cates that the plasminogen binding capacity of breast cancer cells
modulates plasmin activity in the presence of uPA and, taken
together, establishes a relationship between the plasminogen
binding capacity of breast cancer cells and their metastatic poten-
tial, at least in an in vitro model.
The differences in cell-surface plasminogen binding between
the metastatic MDA-MB-231 cells vs the non-metastatic MCF-7
and T-47D cells are possibly related to the ability of cells to target
some or all of their plasminogen binding proteins to the cell
surface. One possible mechanism may be linked to the difference
in uPA/uPAR status between the cell lines. Incubation of the
WISH epithelial cell line, which expresses high levels ofuPAR but
undetectable levels of uPA, with inactive uPA resulted in the
phosphorylation and redistribution ofthe cytoskeletal components
cytokeratin 8 and 18 (Busso et al, 1994). From this, it was
suggested that signal transduction pathways via the uPAR GPI
anchor are involved in cell migration (Busso et al, 1994). As
cytokeratin 8 has been shown to be a plasminogen receptor associ-
ated with the external surfaces of human breast cancer cells
(Hembrough et al, 1995, 1996), signal transduction events associ-
ated with uPAR expression may be one mechanism that leads to an
increased capacity of breast cancer cells, such as the MDA-MB-
231 cells, to bind cell-surface plasminogen.
It is conceivable that variations in the activity of intracellular
signalling proteins due to EGFR and erbB-21neu expression may
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initiate events that lead to the translocation of proteins within the
cell (Milligan et al, 1995) and may in some way affect the local-
ization of proteins that can act as plasminogen receptors if placed
in the correct orientation at the cell surface. Amino-or carboxy-
terminal lysines appear to be the only feature common and
necessary to all candidate plasminogen binding proteins. Any
intracellular protein with an amino- or carboxy-terminal lysine
that is also subject to the above modifications could be trans-
located to the outer surface of the plasma membrane and act as a
plasminogen receptor.
Other markers whose cellular expression correlates with
metastatic potential have been identified in human breast cancer
cell lines. These include matrix metalloproteinase-2 (Azzam et al,
1993), vimentin (Thompson et al, 1992) and surface glycoproteins
such as CD44 (Culty et al, 1994). However, a review of the litera-
ture indicates that overexpression of components of the plas-
minogen activation cascade play an important role in breast cancer
invasion and metastasis. While stromal cells adjacent to cancer
cells in breast cancer tissue may contribute to invasion, by
expressing uPA and/or uPAR for example (Christensen et al, 1996;
Costantini et al, 1996; Nielsen et al, 1996), our data and that of
others (Holst-Hansen et al, 1996; Stonelake et al, 1997) clearly
show that breast epithelial cells with a metastatic phenotype have
the capacity to efficiently convert plasminogen to plasmin. A
combination of studies suggests that the concentration and spatial
distribution of the combination of uPA, uPAR, PAl-1 and PAI-2
expression in human breast carcinomas allow a better indication of
degree of malignancy (Foekens et al, 1995; Christensen et al,
1996; Costantini et al, 1996). The results presented in this paper
strongly suggest that another component of the plasminogen acti-
vation cascade, i.e. plasminogen receptors, is important and their
role in human breast cancer should be further characterized.
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